{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:06:42Z","timestamp":1793387202388,"version":"4.5.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["671231"],"award-info":[{"award-number":["671231"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["667273"],"award-info":[{"award-number":["667273"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["IHU201301187"],"award-info":[{"award-number":["IHU201301187"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ86820"],"award-info":[{"award-number":["ECTZ86820"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hepatology Rep"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Chronic hepatitis B (CHB), caused by hepatitis B virus (HBV), is a major cause of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. HBV replication is characterized by the synthesis of covalently closed circular (ccc) DNA which is not targeted by antiviral nucleos(t)ide analogues (NUCs) the key modality of standard of care. While HBV replication is successfully suppressed in treated patients, they remain at risk for developing HCC. While functional cure, characterized by loss of HBsAg, is the first goal of novel antiviral therapies, curative treatments eliminating cccDNA remain the ultimate goal. This review summarizes recent advances in the discovery and development of novel therapeutic strategies and their impact on cccDNA biology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>Within the last decade, substantial progress has been made in the understanding of cccDNA biology including the discovery of host dependency factors, epigenetic regulation of cccDNA transcription and immune-mediated degradation. Several approaches targeting cccDNA either in a direct or indirect manner are currently at the stage of discovery, preclinical or early clinical development. Examples include genome-editing approaches, strategies targeting host dependency factors or epigenetic gene regulation, nucleocapsid modulators and immune-mediated degradation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>While direct-targeting cccDNA strategies are still largely at the preclinical stage of development, capsid assembly modulators and immune-based approaches have reached the clinical phase. Clinical trials are ongoing to assess their efficacy and safety in patients including their impact on viral cccDNA. Combination therapies provide additional opportunities to overcome current limitations of individual approaches.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11901-020-00534-w","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:07:16Z","timestamp":1594336036000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting Viral cccDNA for Cure of Chronic Hepatitis B"],"prefix":"10.1007","volume":"19","author":[{"given":"Ga\u00ebtan","family":"Ligat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaku","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloi","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"534_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","volume":"4","author":"GS Cooke","year":"2019","unstructured":"Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, et al. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"534_CR2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet Lond Engl. 2014;384:2053\u201363.","journal-title":"Lancet Lond Engl"},{"key":"534_CR3","doi-asserted-by":"crossref","unstructured":"\u2022 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G (2016) Hepatocellular carcinoma. Nat Rev Dis Primer 2:16018. Important review on liver cancer and hepatocellular carcinoma.","DOI":"10.1038\/nrdp.2016.18"},{"key":"534_CR4","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Schinazi RF, Ehteshami M, Bassit L, Asselah T (2018) Towards HBV curative therapies. Liver Int Off J Int Assoc Study Liver 38 Suppl 1:102\u2013114. Important review summarizing recent therapeutic strategies that are currently being evaluated at the preclinical and clinical stage.","DOI":"10.1111\/liv.13656"},{"key":"534_CR5","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","volume":"62","author":"TJ Liang","year":"2015","unstructured":"Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo J-T, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatol Baltim Md. 2015;62:1893\u2013908.","journal-title":"Hepatol Baltim Md"},{"issue":"Suppl 3","key":"534_CR6","doi-asserted-by":"crossref","first-page":"H33","DOI":"10.1177\/135965350701203S05","volume":"12","author":"R Loomba","year":"2007","unstructured":"Loomba R, Liang TJ. Treatment of chronic hepatitis B. Antivir Ther. 2007;12(Suppl 3):H33\u201341.","journal-title":"Antivir Ther"},{"key":"534_CR7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","volume":"31","author":"MG Ghany","year":"2017","unstructured":"Ghany MG. Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31:299\u2013309.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"534_CR8","doi-asserted-by":"crossref","first-page":"HEP03","DOI":"10.2217\/hep-2017-0024","volume":"5","author":"M Colombo","year":"2018","unstructured":"Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepatic Oncol. 2018;5:HEP03.","journal-title":"Hepatic Oncol"},{"key":"534_CR9","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802\u201313.","journal-title":"JAMA"},{"key":"534_CR10","doi-asserted-by":"crossref","unstructured":"Do A, Reau NS (2020) Chronic viral hepatitis: current management and future directions. hepatol commun 4:329\u2013341.","DOI":"10.1002\/hep4.1480"},{"key":"534_CR11","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64:1972\u20131984. Important review summarizing current knowledge on cccDNA molecular biology and potentially curative therapies.","DOI":"10.1136\/gutjnl-2015-309809"},{"key":"534_CR12","unstructured":"\u2022\u2022 Revill PA, Chisari FV, Block JM, et al (2019) A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 4:545\u2013558. Important review summarizing the strategy to cure HBV."},{"key":"534_CR13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67:847\u201361.","journal-title":"J Hepatol"},{"key":"534_CR14","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Verrier ER, Colpitts CC, Bach C, et al (2016) A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. Hepatol Baltim Md 63:35\u201348. This study identified GPC5 as an entry factor for HBV and HDV.","DOI":"10.1002\/hep.28013"},{"key":"534_CR15","unstructured":"\u2022\u2022 Yan H, Zhong G, Xu G, et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049. This study identified NTCP as an entry factor for HBV and HDV."},{"key":"534_CR16","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ni Y, Lempp FA, Mehrle S, et al (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146:1070-1083.e6. Human NTCP is a specific receptor for HBV and HDV.","DOI":"10.1053\/j.gastro.2013.12.024"},{"key":"534_CR17","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.1811064116","volume":"116","author":"M Iwamoto","year":"2019","unstructured":"Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci U S A. 2019;116:8487\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"534_CR18","doi-asserted-by":"crossref","unstructured":"\u2022 Beck J, Nassal M (2007) Hepatitis B virus replication. World J Gastroenterol 13:48\u201364. Important review summarizing the HBV replication.","DOI":"10.3748\/wjg.v13.i1.48"},{"key":"534_CR19","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/jvi.69.6.3350-3357.1995","volume":"69","author":"JE Newbold","year":"1995","unstructured":"Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69:3350\u20137.","journal-title":"J Virol"},{"key":"534_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01703079","volume":"8","author":"CT Bock","year":"1994","unstructured":"Bock CT, Schranz P, Schr\u00f6der CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 1994;8:215\u201329.","journal-title":"Virus Genes"},{"key":"534_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","volume":"307","author":"CT Bock","year":"2001","unstructured":"Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001;307:183\u201396.","journal-title":"J Mol Biol"},{"key":"534_CR22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","volume":"51","author":"M Levrero","year":"2009","unstructured":"Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581\u201392.","journal-title":"J Hepatol"},{"key":"534_CR23","doi-asserted-by":"crossref","unstructured":"Allweiss L, Dandri M (2017) The role of cccDNA in HBV maintenance. Viruses. 21;9(6):156.","DOI":"10.3390\/v9060156"},{"key":"534_CR24","first-page":"653","volume":"90","author":"D Carroll","year":"2017","unstructured":"Carroll D. Genome editing: past, present, and future. Yale J Biol Med. 2017;90:653\u20139.","journal-title":"Yale J Biol Med"},{"key":"534_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cld.735","volume":"12","author":"MG Ghany","year":"2018","unstructured":"Ghany MG, Block TM. Disease pathways and mechanisms of potential drug targets. Clin Liver Dis. 2018;12:12\u20138.","journal-title":"Clin Liver Dis"},{"key":"534_CR26","doi-asserted-by":"crossref","unstructured":"Bloom K, Maepa MB, Ely A, Arbuthnot P (2018) Gene therapy for chronic HBV-can we eliminate cccDNA? Genes. 12;9(4):207.","DOI":"10.3390\/genes9040207"},{"key":"534_CR27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR\/Cas systems. Science. 2013;339:819\u201323.","journal-title":"Science"},{"key":"534_CR28","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117\u201331.","journal-title":"J Hepatol"},{"key":"534_CR29","first-page":"258","volume":"7","author":"A Zhu","year":"2019","unstructured":"Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, et al. HBV cccDNA and its potential as a therapeutic target. J Clin Transl Hepatol. 2019;7:258\u201362.","journal-title":"J Clin Transl Hepatol"},{"key":"534_CR30","doi-asserted-by":"crossref","unstructured":"Lee C (2019) CRISPR\/Cas9-based antiviral strategy: current status and the potential challenge. Mol Basel Switz. 5;24(7):1349.","DOI":"10.3390\/molecules24071349"},{"key":"534_CR31","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","volume":"5","author":"V Ramanan","year":"2015","unstructured":"Ramanan V, Shlomai A, Cox DBT, Schwartz RE, Michailidis E, Bhatta A, et al. CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5:10833.","journal-title":"Sci Rep"},{"key":"534_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","volume":"118","author":"C Dong","year":"2015","unstructured":"Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S. Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication. Antivir Res. 2015;118:110\u20137.","journal-title":"Antivir Res"},{"key":"534_CR33","first-page":"908","volume":"18","author":"A El-Kenawy","year":"2019","unstructured":"El-Kenawy A, Benarba B, Neves AF, de Araujo TG, Tan BL, Gouri A. Gene surgery: potential applications for human diseases. EXCLI J. 2019;18:908\u201330.","journal-title":"EXCLI J"},{"key":"534_CR34","first-page":"91","volume":"7","author":"H Li","year":"2017","unstructured":"Li H, Sheng C, Wang S, et al. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91.","journal-title":"Front Cell Infect Microbiol"},{"issue":"Suppl 1","key":"534_CR35","first-page":"102","volume":"38","author":"RF Schinazi","year":"2018","unstructured":"Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int Off J Int Assoc Study Liver. 2018;38(Suppl 1):102\u201314.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"534_CR36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jgg.2019.11.002","volume":"46","author":"J Li","year":"2019","unstructured":"Li J, Hong S, Chen W, Zuo E, Yang H. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing. J Genet Genomics Yi Chuan Xue Bao. 2019;46:513\u201321.","journal-title":"J Genet Genomics Yi Chuan Xue Bao"},{"key":"534_CR37","doi-asserted-by":"crossref","first-page":"13734","DOI":"10.1038\/srep13734","volume":"5","author":"M Karimova","year":"2015","unstructured":"Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, et al. CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep. 2015;5:13734.","journal-title":"Sci Rep"},{"key":"534_CR38","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1002\/jcb.27050","volume":"119","author":"J Song","year":"2018","unstructured":"Song J, Zhang X, Ge Q, Yuan C, Chu L, Liang H-F, et al. CRISPR\/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem. 2018;119:8419\u201331.","journal-title":"J Cell Biochem"},{"key":"534_CR39","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","volume":"21","author":"T Sakuma","year":"2016","unstructured":"Sakuma T, Masaki K, Abe-Chayama H, Mochida K, Yamamoto T, Chayama K. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells Devoted Mol Cell Mech. 2016;21:1253\u201362.","journal-title":"Genes Cells Devoted Mol Cell Mech"},{"key":"534_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13036-018-0127-2","volume":"12","author":"A Biagioni","year":"2018","unstructured":"Biagioni A, Laurenzana A, Margheri F, Chill\u00e0 A, Fibbi G, Del Rosso M. Delivery systems of CRISPR\/Cas9-based cancer gene therapy. J Biol Eng. 2018;12:33.","journal-title":"J Biol Eng"},{"key":"534_CR41","doi-asserted-by":"crossref","unstructured":"\u2022 Ran FA, Cong L, Yan WX, et al (2015) In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186\u2013191. Study demonstrating that SaCas9 can mediate genome editing in vivo with high specificity.","DOI":"10.1038\/nature14299"},{"key":"534_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2018.02.011","volume":"152","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhao M, Gong M, Xu Y, Xie C, Deng H, et al. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus. Antivir Res. 2018;152:58\u201367.","journal-title":"Antivir Res"},{"key":"534_CR43","doi-asserted-by":"crossref","unstructured":"Scott T, Moyo B, Nicholson S, Maepa MB, Watashi K, Ely A, Weinberg MS, Arbuthnot P (2017) ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep 7:7401.","DOI":"10.1038\/s41598-017-07642-6"},{"key":"534_CR44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.01.013","volume":"70","author":"L Wang","year":"2019","unstructured":"Wang L, Zhu Q, Zeng J, Yan Z, Feng A, Young J, et al. PS-074-A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver. J Hepatol. 2019;70:e48.","journal-title":"J Hepatol"},{"key":"534_CR45","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.00473-12","volume":"56","author":"D Cai","year":"2012","unstructured":"Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012;56:4277\u201388.","journal-title":"Antimicrob Agents Chemother"},{"key":"534_CR46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.coviro.2015.07.009","volume":"14","author":"TF Baumert","year":"2015","unstructured":"Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41\u20136.","journal-title":"Curr Opin Virol"},{"key":"534_CR47","doi-asserted-by":"crossref","unstructured":"Mohd-Ismail NK, Lim Z, Gunaratne J, Tan Y-J (2019) Mapping the interactions of HBV cccDNA with host factors. Int J Mol Sci. 1;20(17):4276.","DOI":"10.3390\/ijms20174276"},{"key":"534_CR48","doi-asserted-by":"crossref","unstructured":"\u2022 K\u00f6niger C, Wingert I, Marsmann M, R\u00f6sler C, Beck J, Nassal M (2014) Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A 111:E4244-4253. This study identified TDP2 as HBV host factor crucial for cccDNA formation.","DOI":"10.1073\/pnas.1409986111"},{"key":"534_CR49","volume":"12","author":"Y Qi","year":"2016","unstructured":"Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, et al. DNA polymerase \u03ba is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016;12:e1005893.","journal-title":"PLoS Pathog"},{"key":"534_CR50","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bbrc.2016.11.085","volume":"482","author":"W Kinoshita","year":"2017","unstructured":"Kinoshita W, Ogura N, Watashi K, Wakita T. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. Biochem Biophys Res Commun. 2017;482:638\u201344.","journal-title":"Biochem Biophys Res Commun"},{"key":"534_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007124","volume":"14","author":"K Kitamura","year":"2018","unstructured":"Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K, et al. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog. 2018;14:e1007124.","journal-title":"PLoS Pathog"},{"key":"534_CR52","volume":"13","author":"Q Long","year":"2017","unstructured":"Long Q, Yan R, Hu J, Cai D, Mitra B, Kim ES, et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog. 2017;13:e1006784.","journal-title":"PLoS Pathog"},{"key":"534_CR53","doi-asserted-by":"crossref","unstructured":"Luo J, Luckenbaugh L, Hu H, Yan Z, Gao L, Hu J (2020) Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation. mBio. 18;11(1):e03423-19.","DOI":"10.1128\/mBio.03423-19"},{"key":"534_CR54","doi-asserted-by":"publisher","unstructured":"\u2022 Wei L, Ploss A (2020) Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. In press. doi: https:\/\/doi.org\/10.1038\/s41564-020-0678-0. A important study identify the minimal set of factors for cccDNA formation.","DOI":"10.1038\/s41564-020-0678-0"},{"key":"534_CR55","doi-asserted-by":"crossref","unstructured":"Schreiner S, Nassal M (2017) A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond? Viruses. 22;9(5):125.","DOI":"10.3390\/v9050125"},{"key":"534_CR56","doi-asserted-by":"publisher","unstructured":"Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev In press doi. 2020. https:\/\/doi.org\/10.1002\/med.21664.","DOI":"10.1002\/med.21664"},{"issue":"2","key":"534_CR57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","volume":"42","author":"M Dandri","year":"2020","unstructured":"Dandri M. Epigenetic modulation in chronic hepatitis B virus infection. Semin Immunopathol. 2020;42(2):173\u201385.","journal-title":"Semin Immunopathol"},{"key":"534_CR58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","volume":"487","author":"SG Deeks","year":"2012","unstructured":"Deeks SG. HIV: Shock and kill. Nature. 2012;487:439\u201340.","journal-title":"Nature"},{"key":"534_CR59","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","volume":"119","author":"SK Ghosh","year":"2012","unstructured":"Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119:1008\u201317.","journal-title":"Blood"},{"key":"534_CR60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2893.2010.01315.x","volume":"17","author":"M Quasdorff","year":"2010","unstructured":"Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat. 2010;17:527\u201336.","journal-title":"J Viral Hepat"},{"key":"534_CR61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1478-3231.2010.02423.x","volume":"31","author":"I Bar-Yishay","year":"2011","unstructured":"Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. Liver Int Off J Int Assoc Study Liver. 2011;31:282\u201390.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"534_CR62","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jhep.2011.02.015","volume":"55","author":"J Lucifora","year":"2011","unstructured":"Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011;55:996\u20131003.","journal-title":"J Hepatol"},{"key":"534_CR63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature17170","volume":"531","author":"A Decorsi\u00e8re","year":"2016","unstructured":"Decorsi\u00e8re A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B virus X protein identifies the Smc5\/6 complex as a host restriction factor. Nature. 2016;531:386\u20139.","journal-title":"Nature"},{"key":"534_CR64","doi-asserted-by":"crossref","unstructured":"\u2022 Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M (2012) IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin invest 122:529\u2013537. This study identified that IFN-\u03b1 mediates epigenetic repression of HBV cccDNA transcription.","DOI":"10.1172\/JCI58847"},{"key":"534_CR65","volume":"9","author":"F Liu","year":"2013","unstructured":"Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9:e1003613.","journal-title":"PLoS Pathog"},{"key":"534_CR66","volume":"10","author":"GA Palumbo","year":"2015","unstructured":"Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One. 2015;10:e0142599.","journal-title":"PLoS One"},{"key":"534_CR67","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.23226","volume":"50","author":"M H\u00f6sel","year":"2009","unstructured":"H\u00f6sel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatol Baltim Md. 2009;50:1773\u201382.","journal-title":"Hepatol Baltim Md"},{"key":"534_CR68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature14192","volume":"517","author":"D Sch\u00fcbeler","year":"2015","unstructured":"Sch\u00fcbeler D. Function and information content of DNA methylation. Nature. 2015;517:321\u20136.","journal-title":"Nature"},{"key":"534_CR69","volume":"9","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One. 2014;9:e110442.","journal-title":"PLoS One"},{"key":"534_CR70","doi-asserted-by":"crossref","unstructured":"\u2022 Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130:823\u2013837. Identification of the enzymatic activities that modulate the acetylation of cccDNA-bound histones as new therapeutic targets for HBV cure.","DOI":"10.1053\/j.gastro.2006.01.001"},{"key":"534_CR71","doi-asserted-by":"crossref","first-page":"104619","DOI":"10.1016\/j.antiviral.2019.104619","volume":"172","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Zhao K, Yao Y, Liu C, Chen Y, Li J, et al. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. Antivir Res. 2019;172:104619.","journal-title":"Antivir Res"},{"key":"534_CR72","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.7150\/ijms.26125","volume":"15","author":"H-B Yu","year":"2018","unstructured":"Yu H-B, Jiang H, Cheng S-T, Hu Z-W, Ren J-H, Chen J. AGK2, a SIRT2 inhibitor inhibits hepatitis B virus replication in vitro and in vivo. Int J Med Sci. 2018;15:1356\u201364.","journal-title":"Int J Med Sci"},{"key":"534_CR73","doi-asserted-by":"crossref","first-page":"s690","DOI":"10.1016\/S0168-8278(17)31855-X","volume":"66","author":"S Gilmore","year":"2017","unstructured":"Gilmore S, Tam D, Dick R, Cheung T, Appleby T, Birkus G, et al. SAT-160 antiviral activityof GS-5801, a liver-targeted prodrug of a lysine demethylase 5 inhibitor, in a hepatitis B virus primary human hepatocyte infection model. J Hepatol. 2017;66:s690\u20131.","journal-title":"J Hepatol"},{"key":"534_CR74","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/hep.24195","volume":"53","author":"X Zhang","year":"2011","unstructured":"Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatol Baltim Md. 2011;53:1476\u201385.","journal-title":"Hepatol Baltim Md"},{"key":"534_CR75","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.7150\/thno.34273","volume":"9","author":"J Feng","year":"2019","unstructured":"Feng J, Yang G, Liu Y, Gao Y, Zhao M, Bu Y, et al. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics. 2019;9:5227\u201345.","journal-title":"Theranostics"},{"key":"534_CR76","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1111\/febs.14094","volume":"284","author":"KO Hensel","year":"2017","unstructured":"Hensel KO, Rendon JC, Navas M-C, Rots MG, Postberg J. Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies. FEBS J. 2017;284:3550\u201372.","journal-title":"FEBS J"},{"key":"534_CR77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","volume":"121","author":"A Zlotnick","year":"2015","unstructured":"Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: a pleiotropic keystone in the HBV lifecycle. Antivir Res. 2015;121:82\u201393.","journal-title":"Antivir Res"},{"key":"534_CR78","doi-asserted-by":"crossref","unstructured":"Berke JM, Dehertogh P, Vergauwen K, Van Damme E, Mostmans W, Vandyck K, Pauwels F (2017) Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus. Antimicrob Agents Chemother. 25;61(8):e00560-17.","DOI":"10.1128\/AAC.00560-17"},{"issue":"Suppl 1","key":"534_CR79","first-page":"27","volume":"40","author":"MG Martinez","year":"2020","unstructured":"Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int Off J Int Assoc Study Liver. 2020;40(Suppl 1):27\u201334.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"534_CR80","volume":"13","author":"F Guo","year":"2017","unstructured":"Guo F, Zhao Q, Sheraz M, Cheng J, Qi Y, Su Q, et al. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog. 2017;13:e1006658.","journal-title":"PLoS Pathog"},{"key":"534_CR81","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/epi.6.6.15815","volume":"6","author":"Y-H Guo","year":"2011","unstructured":"Guo Y-H, Li Y-N, Zhao J-R, Zhang J, Yan Z. HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics. 2011;6:720\u20136.","journal-title":"Epigenetics"},{"key":"534_CR82","doi-asserted-by":"crossref","unstructured":"\u2022 Lucifora J, Xia Y, Reisinger F, et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221\u20131228. A strategy for elimination of cccDNA by APOBEC3.","DOI":"10.1126\/science.1243462"},{"key":"534_CR83","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","volume":"5","author":"X Zhang","year":"2019","unstructured":"Zhang X, Cheng J, Ma J, Hu Z, Wu S, Hwang N, et al. Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors. ACS Infect Dis. 2019;5:759\u201368.","journal-title":"ACS Infect Dis"},{"key":"534_CR84","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.01091-13","volume":"57","author":"G Wu","year":"2013","unstructured":"Wu G, Liu B, Zhang Y, Li J, Arzumanyan A, Clayton MM, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother. 2013;57:5344\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"534_CR85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","volume":"54","author":"O Weber","year":"2002","unstructured":"Weber O, Schlemmer K-H, Hartmann E, Hagelschuer I, Paessens A, Graef E, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antivir Res. 2002;54:69\u201378.","journal-title":"Antivir Res"},{"key":"534_CR86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025096","volume":"6","author":"N Brezillon","year":"2011","unstructured":"Brezillon N, Brunelle M-N, Massinet H, Giang E, Lamant C, DaSilva L, et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA\/SCID mice. PLoS One. 2011;6:e25096.","journal-title":"PLoS One"},{"key":"534_CR87","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/S0960-894X(00)00544-8","volume":"10","author":"RB Perni","year":"2000","unstructured":"Perni RB, Conway SC, Ladner SK, Zaifert K, Otto MJ, King RW. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg Med Chem Lett. 2000;10:2687\u201390.","journal-title":"Bioorg Med Chem Lett"},{"key":"534_CR88","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","volume":"46","author":"WE Delaney","year":"2002","unstructured":"Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, et al. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002;46:3057\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"534_CR89","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","volume":"42","author":"RW King","year":"1998","unstructured":"King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (\u2212)beta-L-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine. Antimicrob Agents Chemother. 1998;42:3179\u201386.","journal-title":"Antimicrob Agents Chemother"},{"key":"534_CR90","doi-asserted-by":"crossref","unstructured":"C Campagna MR, Liu F, Mao R, et al (2013) Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87:6931\u20136942.","DOI":"10.1128\/JVI.00582-13"},{"key":"534_CR91","doi-asserted-by":"crossref","unstructured":"Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F (2020) Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379. Antimicrob Agents Chemother. 21;64(5):e02439-19.","DOI":"10.1128\/AAC.02439-19"},{"key":"534_CR92","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1021\/acsinfecdis.9b00030","volume":"5","author":"Y Pei","year":"2019","unstructured":"Pei Y, Wang C, Ben H, Wang L, Ma Y, Ma Q, et al. Discovery of new hepatitis B virus capsid assembly modulators by an optimal high-throughput cell-based assay. ACS Infect Dis. 2019;5:778\u201387.","journal-title":"ACS Infect Dis"},{"key":"534_CR93","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1021\/acsmedchemlett.9b00550","volume":"11","author":"HG Na","year":"2020","unstructured":"Na HG, Imran A, Kim K, Han HS, Lee YJ, Kim M-J, et al. Discovery of a new sulfonamide hepatitis B capsid assembly modulator. ACS Med Chem Lett. 2020;11:166\u201371.","journal-title":"ACS Med Chem Lett"},{"key":"534_CR94","doi-asserted-by":"crossref","unstructured":"Lahlali T, Berke JM, Vergauwen K, Foca A, Vandyck K, Pauwels F, Zoulim F, Durantel D (2018) Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle. Antimicrob Agents Chemother. 24;62(10):e00835-18.","DOI":"10.1128\/AAC.00835-18"},{"key":"534_CR95","doi-asserted-by":"crossref","unstructured":"Amblard F, Boucle S, Bassit L, et al (2020) Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice. Antimicrob Agents Chemother. 27;64(2):e01701-19.","DOI":"10.1128\/AAC.01701-19"},{"key":"534_CR96","doi-asserted-by":"crossref","unstructured":"Ko C, Bester R, Zhou X, Xu Z, Blossey C, Sacherl J, Vondran FWR, Gao L, Protzer U (2019) A new role for capsid assembly modulators to target mature hepatitis B virus capsids and prevent virus infection. Antimicrob Agents Chemother. 20;64(1):e01440-19.","DOI":"10.1128\/AAC.01440-19"},{"key":"534_CR97","doi-asserted-by":"publisher","unstructured":"Zoulim F, Lenz O, Vandenbossche JJ, Talloen W, Verbinnen T, Moscalu I, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology In press doi. 2020. https:\/\/doi.org\/10.1053\/j.gastro.2020.04.036.","DOI":"10.1053\/j.gastro.2020.04.036"},{"key":"534_CR98","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4:883\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"534_CR99","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","volume":"5","author":"M-F Yuen","year":"2020","unstructured":"Yuen M-F, Agarwal K, Gane EJ, Schwabe C, Ahn SH, Kim DJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5:152\u201366.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"534_CR100","doi-asserted-by":"crossref","unstructured":"Yuen MF, Gane EJ, Kim DJ, et al (2019) Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 156:1392-1403.e7.","DOI":"10.1053\/j.gastro.2018.12.023"},{"key":"534_CR101","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1053\/jhep.2003.50389","volume":"38","author":"J Feld","year":"2003","unstructured":"Feld J, Lee J, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatol Baltim Md. 2003;38:545\u201353.","journal-title":"Hepatol Baltim Md"},{"key":"534_CR102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","volume":"58","author":"FV Chisari","year":"2010","unstructured":"Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010;58:258\u201366.","journal-title":"Pathol Biol (Paris)"},{"key":"534_CR103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.gastro.2015.09.026","volume":"150","author":"Y Xia","year":"2016","unstructured":"Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, H\u00f6sel M, et al. Interferon-\u03b3 and tumor necrosis factor-\u03b1 produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150:194\u2013205.","journal-title":"Gastroenterology"},{"key":"534_CR104","doi-asserted-by":"crossref","unstructured":"Boni C, Vecchi A, Rossi M, et al (2018) TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Gastroenterology 154:1764-1777.e7.","DOI":"10.1053\/j.gastro.2018.01.030"},{"key":"534_CR105","doi-asserted-by":"crossref","unstructured":"Ma Z, Cao Q, Xiong Y, Zhang E, Lu M (2018) Interaction between hepatitis B virus and toll-like receptors: current status and potential therapeutic use for chronic hepatitis B. Vaccines. 16;6(1):6.","DOI":"10.3390\/vaccines6010006"},{"key":"534_CR106","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12876-017-0726-2","volume":"17","author":"S Alonso","year":"2017","unstructured":"Alonso S, Guerra A-R, Carreira L, Ferrer J-\u00c1, Guti\u00e9rrez M-L, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol. 2017;17:168.","journal-title":"BMC Gastroenterol"},{"key":"534_CR107","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2017.12.007","volume":"68","author":"C Niu","year":"2018","unstructured":"Niu C, Li L, Daffis S, Lucifora J, Bonnin M, Maadadi S, et al. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism. J Hepatol. 2018;68:922\u201331.","journal-title":"J Hepatol"},{"key":"534_CR108","doi-asserted-by":"crossref","unstructured":"Lanford RE, Guerra B, Chavez D, et al (2013) GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144:1508\u20131517, 1517.e1\u201310.","DOI":"10.1053\/j.gastro.2013.02.003"},{"key":"534_CR109","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","volume":"62","author":"S Menne","year":"2015","unstructured":"Menne S, Tumas DB, Liu KH, Thampi L, AlDeghaither D, Baldwin BH, et al. Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B. J Hepatol. 2015;62:1237\u201345.","journal-title":"J Hepatol"},{"key":"534_CR110","doi-asserted-by":"crossref","unstructured":"Agarwal K, Ahn SH, Elkhashab M, et al (2018) Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat 25:1331\u20131340111. Lopatin U (2019) Drugs in the Pipeline for HBV. Clin Liver Dis 23:535\u2013555.","DOI":"10.1111\/jvh.12942"},{"key":"534_CR111","doi-asserted-by":"crossref","first-page":"S692","DOI":"10.1016\/S0168-8278(17)31859-7","volume":"66","author":"S Daffis","year":"2017","unstructured":"Daffis S, Chamberlain J, Zheng J, Santos R, Rowe W, Mish M, et al. Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688. J Hepatol. 2017;66:S692\u20133.","journal-title":"J Hepatol"},{"key":"534_CR112","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","volume":"574","author":"AP B\u00e9n\u00e9chet","year":"2019","unstructured":"B\u00e9n\u00e9chet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019;574:200\u20135.","journal-title":"Nature"},{"key":"534_CR113","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/hep.21482","volume":"45","author":"K Visvanathan","year":"2007","unstructured":"Visvanathan K, Skinner NA, Thompson AJV, Riordan SM, Sozzi V, Edwards R, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatol Baltim Md. 2007;45:102\u201310.","journal-title":"Hepatol Baltim Md"},{"key":"534_CR114","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clim.2008.04.006","volume":"128","author":"Z Chen","year":"2008","unstructured":"Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, et al. Expression profiles and function of toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol Orlando Fla. 2008;128:400\u20138.","journal-title":"Clin Immunol Orlando Fla"},{"key":"534_CR115","doi-asserted-by":"crossref","unstructured":"\u2022 Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q (2015) Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Antivir Ther 20:591\u2013602. This study characterized the immunological features responsible for treatment responses with pegylated interferon (PEG-IFN)-\u03b12a in entecavir (ETV)-suppressed patients with CHB.","DOI":"10.3851\/IMP2953"},{"key":"534_CR116","doi-asserted-by":"crossref","unstructured":"\u2022 Visvanathan K, Lang T, Ryan K, et al (2016) Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. J Viral Hepat 23:170\u2013179. This study suggested clinical differences observed across the CHB spectrum.","DOI":"10.1111\/jvh.12477"},{"key":"534_CR117","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jhep.2015.06.022","volume":"63","author":"S Luangsay","year":"2015","unstructured":"Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, et al. Expression and functionality of toll- and RIG-like receptors in HepaRG cells. J Hepatol. 2015;63:1077\u201385.","journal-title":"J Hepatol"},{"key":"534_CR118","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1038\/s41598-018-23525-w","volume":"8","author":"J Lucifora","year":"2018","unstructured":"Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, et al. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Sci Rep. 2018;8:5390.","journal-title":"Sci Rep"},{"key":"534_CR119","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/hep.30054","volume":"68","author":"ER Verrier","year":"2018","unstructured":"Verrier ER, Yim S, Heydmann L, et al. Hepatitis B virus evasion from cyclic guanosine monophosphate\u2013adenosine monophosphate synthase sensing in human hepatocytes. Hepatology. 2018;68:1695\u2013709.","journal-title":"Hepatology"},{"key":"534_CR120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161313","volume":"11","author":"KE Korolowicz","year":"2016","unstructured":"Korolowicz KE, Iyer RP, Czerwinski S, Suresh M, Yang J, Padmanabhan S, et al. Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the woodchuck model of chronic hepatitis B. PLoS One. 2016;11:e0161313.","journal-title":"PLoS One"},{"key":"534_CR121","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","volume":"64","author":"A Bertoletti","year":"2016","unstructured":"Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64:S71\u201383.","journal-title":"J Hepatol"},{"key":"534_CR122","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","volume":"156","author":"B Rehermann","year":"2019","unstructured":"Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology. 2019;156:369\u201383.","journal-title":"Gastroenterology"},{"key":"534_CR123","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12072-018-9912-8","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Neumann-Haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int. 2019;13:113\u201324.","journal-title":"Hepatol Int"},{"key":"534_CR124","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","volume":"156","author":"AJ Gehring","year":"2019","unstructured":"Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology. 2019;156:325\u201337.","journal-title":"Gastroenterology"},{"key":"534_CR125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","volume":"12","author":"A Bertoletti","year":"2018","unstructured":"Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver. 2018;12:497\u2013507.","journal-title":"Gut Liver"},{"key":"534_CR126","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Hoogeveen RC, Boonstra A (2020) Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol 11:401. A review summarizing current knowledge on checkpoint inhibitors and therapeutic vaccines against HBV infection.","DOI":"10.3389\/fimmu.2020.00401"},{"key":"534_CR127","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/21645515.2016.1276125","volume":"13","author":"J Li","year":"2017","unstructured":"Li J, Bao M, Ge J, Ren S, Zhou T, Qi F, et al. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccines Immunother. 2017;13:986\u201397.","journal-title":"Hum Vaccines Immunother"},{"key":"534_CR128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines8020184","volume":"8","author":"SK Chinnakannan","year":"2020","unstructured":"Chinnakannan SK, Cargill TN, Donnison TA, Ansari MA, Sebastian S, Lee LN, et al. The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia Ankara viral vectors; a novel therapeutic vaccine strategy against HBV. Vaccines. 2020;8:184.","journal-title":"Vaccines"},{"key":"534_CR129","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cbdd.13677","volume":"95","author":"M Kalim","year":"2020","unstructured":"Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: a dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des In press doi. 2020;95:552\u201366. https:\/\/doi.org\/10.1111\/cbdd.13677.","journal-title":"Chem Biol Drug Des In press doi"},{"key":"534_CR130","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog. 2014;10:e1003856.","journal-title":"PLoS Pathog"},{"key":"534_CR131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12916-017-0820-x","volume":"15","author":"T-C Tseng","year":"2017","unstructured":"Tseng T-C, Kao J-H. Elimination of hepatitis B: is it a mission possible? BMC Med. 2017;15:53.","journal-title":"BMC Med"},{"key":"534_CR132","volume":"99","author":"D Pu","year":"2020","unstructured":"Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore). 2020;99:e19013.","journal-title":"Medicine (Baltimore)"},{"key":"534_CR133","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"534_CR134","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1097\/QAD.0000000000001599","volume":"31","author":"AC Lake","year":"2017","unstructured":"Lake AC. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. AIDS Lond Engl. 2017;31:2115\u20138.","journal-title":"AIDS Lond Engl"}],"container-title":["Current Hepatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-020-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11901-020-00534-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-020-00534-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:36:24Z","timestamp":1696379784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11901-020-00534-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s11901-020-00534-w","relation":{},"ISSN":["2195-9595"],"issn-type":[{"value":"2195-9595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"10 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors do not report conflict of interest. The research organization of T. F. B. has received a research grant in a collaborative research agreement with Janssen Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}